CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma

Sicong Zhang1, Huilai Zhang1, Xianhuo Wang1

  • 1State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

Abstract

No abstract available in PubMed .

Related Concept Videos